Postmarketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: an Analysis of the FDA Adverse Events Reporting System (FAERS) Database
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.